Sarepta Therapeutics, Inc. (NASDAQ:SRPT) shares have more than 49.87 percent upside potential from the existing levels. This is based on the revised price target of HC Wainwright at $ 221.00 on the stock. Incidentally, the brokerage slashed its price objective by $ 39 from its earlier level of $ 260.00. However, HC Wainwright has maintained its Buy rating on the stock, Benzinga reported.
Shares of Sarepta Therapeutics, Inc. traded low $ -0.29 or -0.20 percent on Monday, reaching $ 147.17 with volume of 190.30 thousand shares. The stock opened positive for the day at $ 147.52, after closing the previous day trading at $ 147.46. According to the previous trading day, closing price of $ 147.46, representing a 104.66 % increase from the 52 week low of $ 72.05 and a 15.74 % decrease over the 52 week high of $ 175.00.
With respect to the key metrics, Sarepta Therapeutics, Inc. stock has advanced $ 11.36 or 8.00 percent, reaching $ 135.81 during the simple moving average (SMA) period of 200 days. Similarly, the stock has decreased $ -9.74 or -6.00 percent, before arriving at $ 156.91 during the SMA50-day period.
Sarepta Therapeutics, Inc. recently reported second quarter financial results on August 5, 2020, after market close, the Cambridge based company unfold loss for the second quarter of $ 1.51 per share, from the revenue of $ 137.36 million. The quarterly earnings down 39.85 percent while revenues compared with the same quarter last year. According to street consensus, SRPT was expected to report 2Q20 loss of $ 1.72 per share from revenue of $ 118.78 million. The bottom line results beat street analysts by $ 0.21 or 12.21 percent, at the same time, top line results outshined analysts by $ 18.58 million or 15.64 percent.
Moving forward, analysts polled by Thomson Reuters anticipate third quarter loss of $ 1.77 per share from revenue of $ 137.34 million. Looking ahead, the full year loss are expected at $ 5.98 per share on the revenues of $ 566.12 million.
Sarepta Therapeutics, Inc. focuses on the discovery and development of RNA-based therapeutics, gene therapy, and other genetic medicine approaches for the treatment of rare diseases. The company offers EXONDYS 51, a disease-modifying therapy for duchenne muscular dystrophy (DMD).
